Number 4: The FDA and European Medicines Agency (EMA) granted approval, with interchangeability in the US, to Samsung Bioepis ...

For example, underrepresented physicians are more likely to practice in underserved areas, increasing access to care. Research has also shown that health outcomes, such as infant mortality rates ...

A panelist discusses how their institution prioritizes cost savings and reliable supply chain considerations when selecting biosimilars for formulary inclusion, while also weighing switching study ...

For example, in a recent 2024 study my team conducted using biosimilar products in rheumatology and oncology, trends were uncovered in payer coverage, market share, and pricing that reveal that ...

The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab-anoh), a biosimilar to Actemra ® (tocilizumab), in both intravenous (IV) and subcutaneous (SC) formulations. Avtozma, ...

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.

A few examples of biologic drugs that may be used to treat enthesitis are: Various biosimilar compounds are available for the above “branded” biologic agents. Biosimilars may be prescribed by ...

P.C., a seven-office rheumatology practice in Maryland; Washington, DC; and Virginia. Many other biosimilars for rheumatologic medications are launching in the next 2 years, “and we’re very ...

Initial fasting plasma glucose levels outside of 80 to 94mg/dL linked to increased risk for diabetes. HealthDay News — Fasting plasma glucose (FPG), age, body mass index (BMI), and male sex are ...

The FDA has approved a third biosimilar for tocilizumab ... Rheumatologists report largely adhering to American College of Rheumatology guidelines for gout management, but show notable divergence ...

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term competition thanks to a new agreement between Amgen and Celltrion. Late last week ...

Diabetes remission was achieved in 44 and 28% of patients in the dapagliflozin and placebo groups, respectively. HealthDay News — For patients with overweight or obesity and type 2 diabetes ...